Get the Stockscreener App
161.91
3.95%
-6.66
Pre-market:
161.91
Krystal Biotech Inc stock is traded at $161.91, with a volume of 291.39K.
It is down -3.95% in the last 24 hours and down -13.49% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$168.57
Open:
$166.93
24h Volume:
291.39K
Relative Volume:
1.05
Market Cap:
$4.88B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
54.15
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
-4.14%
1M Performance:
-13.49%
6M Performance:
-9.54%
1Y Performance:
+2.13%
1-Day Range:
$161.03
$170.50
1-Week Range:
$161.03
$171.00
52-Week Range:
$141.72
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
161.91 | 4.88B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Top Growth Companies With High Insider Ownership In April 2025 - simplywall.st
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Alliancebernstein L.P. - Defense World
Wellington Management Group LLP Sells 976 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Gene Therapy Market Top Players-Krystal Biotech, Inc., - openPR.com
JPMorgan Chase & Co. Buys 23,934 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Becomes Oversold (KRYS) - Nasdaq
Krystal Biotech subsidiary Jeune Aesthetics taps Botox veteran as new CEO - The Business Journals
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Krystal gets positive EU regulatory opinion for Vyjuvek - MSN
Jeune Aesthetics names Marc Forth as new CEO By Investing.com - Investing.com South Africa
Jeune Aesthetics names Marc Forth as new CEO - Investing.com Australia
Jeune Aesthetics Appoints Marc Forth As Chief Executive Officer - MarketScreener
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewswire
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Zacks Investment Research
Krystal Biotech Q1 EPS Forecast Reduced by William Blair - Defense World
Krystal Biotech: Some Uncertainty, Some Value (NASDAQ:KRYS) - Seeking Alpha
Norges Bank Purchases New Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Raises Earnings Estimates for Krystal Biotech - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Sei Investments Co. - Defense World
Commonwealth Equity Services LLC Boosts Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Commonwealth Equity Services LLC Purchases 190 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - The AM Reporter
(KRYS) Proactive Strategies - news.stocktradersdaily.com
Teacher Retirement System of Texas Purchases 1,369 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Teacher Retirement System of Texas - Defense World
US High Growth Tech Stocks With Promising Potential - Yahoo Finance
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK - Seeking Alpha
How To Trade (KRYS) - news.stocktradersdaily.com
3 High Growth Companies Insiders Are Betting On - simplywall.st
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue? - Yahoo
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $220.00 - Defense World
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Raymond James Financial Inc. Takes $15.99 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Is Krystal Biotech, Inc.'s (NASDAQ:KRYS) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Simply Wall St
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock - Yahoo Finance
US Bancorp DE Grows Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Krystal Biotech president Suma Krishnan sells $8.9 million in shares - Investing.com India
Krystal Biotech president Suma Krishnan sells $8.9 million in shares By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krishnan sells $8.89 million in stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krishnan sells $8.89 million in stock - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Keybank National Association OH - Defense World
How to Take Advantage of moves in (KRYS) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $26.53 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? - Nasdaq
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):